Johnson & Johnson's (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for domestic use.

On January 13, Johnson & Johnson (JNJ.US) announced that its innovative therapeutic drug Erdafitinib (brand name: Beckett) has officially been approved by the National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who carry a sensitive FGFR3 gene mutation and have experienced disease progression during or after receiving at least one line of therapy containing anti-PD-1 or anti-PD-L1.

Cherry Huang, President of Johnson & Johnson's Innovation Pharmaceuticals in China, stated, "Erdafitinib has confirmed the significant benefits and broad application prospects of targeted therapy for advanced bladder cancer patients, highlighting the importance of FGFR gene detection in the diagnosis and treatment of metastatic urothelial carcinoma. As a significant milestone in this field, this approval demonstrates Johnson & Johnson's long-term commitment to advancing precision treatment in the field of oncology and improving patients' survival benefits. In the future, we will continue to focus on areas with significant unmet medical needs, leading the way in science to shape the future of medicine and work hard to manage the entire life cycle of cancer, dedicated to making cancer a controllable and curable chronic disease."